Clinical trials: Waldenstrom's Macroglobulinemia
Waldenström's Macroglobulinemia
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia
A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenström's macroglobulinemia (Ballondor trial)
- Trial name
- Ballondor (NCT03697356)
- Testing
- Lenalidomide, Bortezomib, Rituximab, Dexamethasone
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Kosin University Gospel Hospital
Waldenstrom's Macroglobulinemia
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
This research study is evaluating a drug called idelalisib (formerly known as GS-1101 or CAL-101) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT02439138
- Testing
- GS-1101
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
RATIONALE: Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. Giving combination chemotherapy together with bortezomib, thalidomide, and rituximab before an autologous…
- Trial name
- NCT00723658
- Testing
- rituximab, bortezomib, carmustine
- Where
- 29 sites in United States
- Sponsor
- SWOG Cancer Research Network
Influenza, Multiple Myeloma
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
The investigators' hypothesis is that the administration of Fluzone® High-Dose with booster to all patients with monoclonal gammopathies (irrespective of age) will lead to seroconversion rates exceeding 50% and more importantly…
- Conditions
- Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders
- Trial name
- SHIVERING 2 (NCT02566265)
- Testing
- Fluzone High Dose Vaccine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Yale University
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Primary Objectives: To document the efficacy of treatment with autologous lymphoma-derived HSPPC-96 of selected patients with indolent lymphoma.
- Trial name
- NCT00081809
- Testing
- autologous human tumor-derived HSPPC-96
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Agenus Inc.
Waldenstrom's Macroglobulinemia
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
The purpose of this research study is to assess the overall response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
- Trial name
- NCT00936611
- Testing
- LBH589
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma, Waldenstrom Macroglobulinemia
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
- Conditions
- Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder, Covid19
- Trial name
- NCT04830046
- Where
- 2 sites in United States
- Volunteers
- 146 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Lymphoma
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004107
- Testing
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM
- Trial name
- NCT02071888
- Testing
- CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Calithera Biosciences, Inc
Waldenstrom's Macroglobulinemia
Simvastatin in Waldenstrom's Macroglobulinemia
This research study seeks to find new ways to treat people with Waldenstrom's Macroglobulinemia (WM). The study is for participants with slow growing WM who otherwise might not need therapy for at least 3-6 months.
- Trial name
- NCT00575965
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Waldenstrom Macroglobulinemia, Waldenstrom's Disease
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrӧm's macroglobulinemia (WM). The study will evaluate this combination in two cohorts.
- Conditions
- Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT03679624
- Testing
- Ibrutinib, Daratumumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Lymphoma
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005609
- Testing
- rituximab
- Where
- 69 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoplasmacytic Lymphoma, Waldenstrom's Macroglobulinemia
Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
The purpose of this study is to determine the safety and effects (good or bad) of Campath-1H antibody in the treatment of lymphoplasmacytic lymphoma.
- Trial name
- NCT00142181
- Testing
- Campath-1H
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma, Smoldering Myeloma
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors find better ways to ways to treat the cancer.
- Conditions
- Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT00919139
- Testing
- biologic sample preservation procedure
- Where
- 207 sites in United States
- Volunteers
- 190 people
- Sponsor
- SWOG Cancer Research Network
Waldenstrom's Macroglobulinemia
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
This research study is studying Ulocuplumab combined with ibrutinib as a possible treatment for symptomatic Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT03225716
- Testing
- Ulocuplumab, Ibrutinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Hodgkins Lymphoma, B-cell Lymphoma
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
- Conditions
- Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT01647971
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- TG Therapeutics, Inc.
714leukemia, Lymphoma
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00671112
- Testing
- Bortezomib, Everolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Hill, MD, PhD
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
- Trial name
- NCT02924402
- Testing
- XmAb13676
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 154 people
- Sponsor
- Xencor, Inc.
Waldenstrom Macroglobulinaemia
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of…
- Trial name
- NCT00811733
- Testing
- Ofatumumab
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic…
- Trial name
- NCT04840602
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 146 sites in United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)